nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

09.08.2020 | Original Article – Clinical Oncology

Indications for adjuvant chemotherapy in patients with pT1N1M0 gastric cancer: a single-center experience

verfasst von: Peng Jin, Xiaoyan Ji, Shuai Ma, Wenzhe Kang, Hao Liu, Yang Li, Fuhai Ma, Haitao Hu, Weikun Li, Yantao Tian

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Whether adjuvant chemotherapy (AC) has a survival benefit for all patients with pathological stage pT1N1M0 (Stage IB) gastric cancer (GC) remains controversial.

Methods

All patients with surgically resected, histologically confirmed pT1N1M0 GC between January 2011 and December 2017 at the National Cancer Center, China, were retrospectively reviewed.

Results

A total of 179 patients with pT1N1M0 were identified. Survival analysis showed that both overall survival (OS) and cause-specific survival (CSS) were significantly different between patients treated with and without AC (p < 0.01). Independent risk factors for reduced OS identified in the Cox regression analysis in patients with pT1N1M0 cancer were sex (male sex, hazard ratio [HR] 2.470, 95% confidence interval [CI] 1.294–4.718), examined lymph nodes (EN) (EN ≤ 15, HR 2.402; 95% CI 1.329–4.341), and AC (treated without AC, HR 2.554; 95% CI 1.393–4.681), which were also independent risk factors for reduced CSS. We divided patients with pT1N1M0 into three risk categories (high, moderate, and low) according to two significant prognostic factors (sex and EN) and found that both OS and CSS were significantly different between the three risk groups (p < 0.05).

Conclusion

An additional survival benefit related to AC is expected for selected pT1N1M0 patients. Male patients with EN ≤ 15 may be particularly appropriate candidates for AC.

Amin MB et al (2017) The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more personalized approach to cancer staging. Cancer J Clin 67:93–99. https://doi.org/10.3322/caac.21388CrossRef

Aoyama T et al (2014) Prognostic factors in stage IB gastric cancer. World J Gastroenterol 20:6580–6585. https://doi.org/10.3748/wjg.v20.i21.6580CrossRefPubMedPubMedCentral

Aznab M, Maleksabet D, Khazaei S, Khazaei M, Rezaei M (2019) The role of human epidermal growth factor receptor (HER2/neu) in the prognosis of patients with gastric cancer. Asian Pacific J Cancer Prevent 20:1989–1994. https://doi.org/10.31557/APJCP.2019.20.7.1989CrossRef

Bang YJ et al (2012) Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 379:315–321. https://doi.org/10.1016/S0140-6736(11)61873-4CrossRefPubMed

Boku N et al (2009) Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 10:1063–1069. https://doi.org/10.1016/S1470-2045(09)70259-1CrossRefPubMed

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492CrossRef

Folli S et al (2001) Risk factors for lymph node metastases and their prognostic significance in early gastric cancer (EGC) for the Italian Research Group for Gastric Cancer (IRGGC). Jpn J Clin Oncol 31:495–499. https://doi.org/10.1093/jjco/hye107CrossRefPubMed

Gold JS et al (2013) Population-based outcome of stage IA–IIA resected gastric adenocarcinoma: who should get adjuvant treatment? Ann Surg Oncol 20:2304–2310. https://doi.org/10.1245/s10434-012-2852-yCrossRefPubMed

Guideline Committee of the Korean Gastric Cancer Association DWG, Review P (2019) Korean practice guideline for gastric cancer 2018: an evidence-based multi-disciplinary approach. J Gastric Cancer 19:1–48. https://doi.org/10.5230/jgc.2019.19.e8CrossRef

Hsu JT et al (2013) Prognostic significance of the number of examined lymph nodes in node-negative gastric adenocarcinoma. Eur J Surg Oncol 39:1287–1293. https://doi.org/10.1016/j.ejso.2013.07.183CrossRefPubMed

Information Committee of Korean Gastric Cancer A (2016) Korean gastric cancer association nationwide survey on gastric cancer in 2014. J Gastric Cancer 16:131–140. https://doi.org/10.5230/jgc.2016.16.3.131CrossRef

Jabo B et al (2018) Comparison of perioperative chemotherapy with adjuvant chemoradiotherapy for resectable gastric cancer: findings from a population-based study. J Gastrointest Oncol 9:35–45. https://doi.org/10.21037/jgo.2017.10.13CrossRefPubMedPubMedCentral

Japanese Gastric Cancer A (2020) Japanese gastric cancer treatment guidelines 2018 (5^th edition). Gastric Cancer. https://doi.org/10.1007/s10120-020-01042-yCrossRef

Katai H et al (2018) Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100,000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001–2007). Gastric Cancer 21:144–154. https://doi.org/10.1007/s10120-017-0716-7CrossRefPubMed

Kunisaki C et al (2010) Impact of lymphovascular invasion in patients with stage I gastric cancer. Surgery 147:204–211. https://doi.org/10.1016/j.surg.2009.08.012CrossRefPubMed

Kwon OK et al (2016) Validation of the 7th AJCC/UICC staging system for gastric cancer and a proposal for a new TNM system based on a prognostic score: a retrospective multicenter study. Ann Surg Treat Res 91:295–302. https://doi.org/10.4174/astr.2016.91.6.295CrossRefPubMedPubMedCentral

Lee HJ, Kim YH, Kim WH, Lee KU, Choe KJ, Kim JP, Yang HK (2003) Clinicopathological analysis for recurrence of early gastric cancer. Jpn J Clin Oncol 33:209–214. https://doi.org/10.1093/jjco/hyg042CrossRefPubMed

Li H, Wang C, Wei Z, Chen W, Guo Z, He Y, Zhang C (2019a) Differences in the prognosis of gastric cancer patients of different sexes and races and the molecular mechanisms involved. Int J Oncol 55:1049–1068. https://doi.org/10.3892/ijo.2019.4885CrossRefPubMedPubMedCentral

Li H, Wei Z, Wang C, Chen W, He Y, Zhang C (2019b) Gender differences in gastric cancer survival: 99,922 cases based on the SEER database. J Gastrointest Surg. https://doi.org/10.1007/s11605-019-04304-yCrossRefPubMedPubMedCentral

Lu J et al (2018) Significance of preoperative systemic immune score for stage I gastric cancer patients. Gastroenterol Res Prac 2018:3249436. https://doi.org/10.1155/2018/3249436CrossRef

Macdonald JS et al (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. New Engl J Med 345:725–730. https://doi.org/10.1056/NEJMoa010187CrossRefPubMed

Noh SH et al (2014) Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol 15:1389–1396. https://doi.org/10.1016/S1470-2045(14)70473-5CrossRefPubMed

Ryu ES et al (2019) Sex-specific differences in risk factors of lymph node metastasis in patients with early gastric cancer. PLoS ONE 14:e0224019. https://doi.org/10.1371/journal.pone.0224019CrossRefPubMedPubMedCentral

Sakuramoto S et al (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. New Engl J Med 357:1810–1820. https://doi.org/10.1056/NEJMoa072252CrossRefPubMed

Sasako M et al (2011) Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 29:4387–4393. https://doi.org/10.1200/JCO.2011.36.5908CrossRefPubMed

Shiozawa N, Kodama M, Chida T, Arakawa A, Tur GE, Koyama K (1994) Recurrent death among early gastric cancer patients: 20-years' experience. Hepato-gastroenterol 41:244–247

Wang FH et al (2019a) The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer. Cancer Commun 39:10. https://doi.org/10.1186/s40880-019-0349-9CrossRef

Wang Y et al (2019b) Implication of lymph node staging in migration and different treatment strategies for stage T2N0M0 and T1N1M0 resected gastric cancer: a SEER population analysis. Clin Trans Oncol 21:1499–1509. https://doi.org/10.1007/s12094-019-02078-yCrossRef

Yura M, Yoshikawa T, Otsuki S, Yamagata Y, Morita S, Katai H, Nishida T (2020) Is surgery alone sufficient for treating T1 gastric cancer with extensive lymph node metastases? Gastric Cancer 23:349–355. https://doi.org/10.1007/s10120-019-01006-xCrossRefPubMed

Zheng WF, Ji TT, Lin Y, Li RZ (2016) The prognostic value of lymph nodes count on survival of patients with node-negative gastric cancer. Oncotarget 7:43680–43688. https://doi.org/10.18632/oncotarget.9845CrossRefPubMedPubMedCentral

Titel: Indications for adjuvant chemotherapy in patients with pT1N1M0 gastric cancer: a single-center experience
verfasst von: Peng Jin
Xiaoyan Ji
Shuai Ma
Wenzhe Kang
Hao Liu
Yang Li
Fuhai Ma
Haitao Hu
Weikun Li
Yantao Tian
Publikationsdatum: 09.08.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 2/2021
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-020-03355-y

Neu im Fachgebiet Onkologie

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Indications for adjuvant chemotherapy in patients with pT1N1M0 gastric cancer: a single-center experience